High materiality7/10
Corcept Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
Why it may matterVerify against the original reporting
Significant downside risk implied by downgrade; downside risk outweighs near-term upside.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wolfe Research downgrades CORT to Underperform; target price is $50 while current price is $95.36. The sizable target gap suggests bearish implications despite the target being well below the current price, price has fallen by 3.29 since the signal.
- Wolfe downgrades CORT to Underperform; target $50 vs price $95.36.
Key facts
- 01
Target: $50
- 02
Posted price: $95.36
- 03
Analyst firm: Wolfe Research
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.